The latest research and impact of recent clinical trials on treatment selection using erythropoiesis stimulating and hypomethylating agents for myelodysplastic syndrome.
EP. 2: Clinical Considerations in the Diagnosis of Patients with MDS
July 9th 2021Rami Komrokji, MD, of the H. Lee Moffitt Cancer Center & Research Institute, discusses the importance of examining a patient’s complete blood count, nutritional status and bone marrow when considering a diagnosis of myelodysplastic syndrome.